MedTrace Logo

Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects

NCT04686994 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-09-27

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .

Conditions

Interventions

DRUG

ASC 41

Oral tablets

DRUG

ASC 41 Placebo

Oral tablets

Sponsors & Collaborators

  • Hunan Provincial People's Hospital

    collaborator OTHER

  • Gannex Pharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-22
Primary Completion
2021-01-19
Completion
2021-02-07

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04686994 on ClinicalTrials.gov